NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership
NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership
Aurora's international sales hit C$39.3 million ($28.9 million) in early 2024. This is a 31% increase year-over-year. Growth was aided by acquiring MedReleaf Australia. Aurora now controls over 30% of Canada's medical marijuana exports.Aurora Cannabis Inc. (NASDAQ:ACB) has partnered with Vectura Fertin Pharma, Inc. to launch a CBD lozenge in the form of a dissolvable tablet that delivers the precise dose of cannabidiol (CBD). The new product is expected to enhance patient care by providing an alternative consumption method without psychoactive effects.
大麻股Aurora Cannabis Inc. (納斯達克:ACB)已與Vectura Fertin Pharma, Inc.合作推出一種CBD lozenge，以可溶片劑的形式提供精確劑量的大麻二酚（CBD）。預計新產品將通過提供另一種無精神活性效果的替代消費方式來增強患者護理。
The partnership leverages Aurora's extensive medical cannabis patient platform, said Aurora CEO Miguel Martin, who added that the company intends to broaden Canadian healthcare options with innovative products.
這項合作利用了Aurora廣泛的醫療大麻患者平台，Aurora首席執行官Miguel Martin表示，公司打算通過創新產品拓寬加拿大的醫療保健選擇。
"Our partnership aligns with our commitment to meet Canada's evolving healthcare needs," Martin stated in a press release.
「我們的合作符合我們承諾滿足加拿大不斷髮展的醫療保健需求，」Martin在一份新聞稿中表示。
NASDAQ Cannabis Titan With Global Reach
全球貨幣大麻巨頭納斯達克上市
Aurora's international sales hit C$39.3 million ($28.9 million) in early 2024. This is a 31% increase year-over-year. Growth was aided by acquiring MedReleaf Australia. Aurora now controls over 30% of Canada's medical marijuana exports.
Aurora的國際銷售額在2024年初達到了3930萬加元（2890萬美元）。這是同比增長了31%。收購MedReleaf Australia幫助增長。Aurora現在控制着超過30%的加拿大醫用大麻出口。
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
獲取Benzinga獨家分析以及關於大麻行業和市場的最新資訊，每天免費發送到您的郵箱。點擊此處訂閱我們的新聞稿。如果您認真對待業務，那麼不能錯過。
Profitability And Operational Efficiency in Cannabis
大麻行業的盈利能力和運營效率
Aurora reported increased adjusted cash gross margins rose 69% in June, up from 66% in March. However, operational expenses were 102% of adjusted cash gross profits. Still, Aurora's net cash position rose to C$63 million. Positive operating cash flows reached C$8.4 million for the quarter.
Aurora報告稱，調整後的現金毛利潤在6月份上升了69%，從3月的66%上升。然而，運營費用佔調整後的現金毛利潤的102%。儘管如此，Aurora的淨現金位置上升至6300萬加元。本季度的正面經營現金流達到了840萬加元。
Valuation And Market Position
估值和市場地位
Aurora Cannabis is valued at C$516 million with an enterprise value of C$543 million. It trades at 1.6 times its current sales, lower than competitors like Tilray (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC). A recent analysis done by Pablo Zuanic highlighted Aurora's solid financial and operational performance, maintaining an attractive valuation compared to its peers.
極光大麻的估值爲C$51600萬，企業價值爲C$54300萬。它的交易價格爲當前銷售額的1.6倍，低於競爭對手如Tilray（納斯達克：TLRY）和canopy growth（納斯達克：CGC）。Pablo Zuanic最近進行的分析強調了極光在財務和運營業績方面的穩健表現，保持着與同行相比具有吸引力的估值。
譯文內容由第三人軟體翻譯。